{
    "clinical_study": {
        "@rank": "102354", 
        "acronym": "ICC H5", 
        "arm_group": {
            "arm_group_label": "Intestinal Delivery", 
            "arm_group_type": "Experimental", 
            "description": "ND1.1"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine the safety and tolerability of ND1.1, an adjuvanted\n      adenoviral-based avian influenza vaccine, when delivery is targeted to the ileum, using a\n      radio controlled capsule. The secondary objective is to evaluate the immune response\n      (cellular and humoral) of two doses of ND1.1 oral vaccine."
        }, 
        "brief_title": "Immunogenicity of ND1.1 by Delivery Directly to the Ileum", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Avian Influenza", 
        "condition_browse": {
            "mesh_term": [
                "Influenza in Birds", 
                "Influenza, Human"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able and willing to complete informed consent\n\n          -  Healthy, as established by medical history, physical exam, and laboratory assessments\n\n          -  Has normal bowel movements\n\n          -  Willing to abstain from caffeine and xanthine containing substances for 24 hours\n             before procedure until after discharge\n\n        Exclusion Criteria:\n\n          -  Ability to donate up to 550 ml of blood over several months\n\n          -  Exposure to any investigational drug or vaccine 8 weeks prior to study\n\n          -  Has traveled to Asia within 8 weeks of enrollment\n\n          -  Abnormal ECG findings\n\n          -  History of irritable bowl or any other inflammatory gastrointestinal disorder\n\n          -  Any individual with increased risk for bowl obstruction\n\n          -  Radiation exposure above target values 50 mSv within the past 30 days or a cumulative\n             dose above 150 mSv in the past 12 months\n\n          -  History of substance abuse\n\n          -  Subject unwilling to use an approved method of contraception during study and for 2\n             months after study\n\n          -  Positive for HCV, HIV, or HBV\n\n          -  Presence of an implantable device that is sensitive to radio frequencies (e.g.\n             pacemakers)\n\n          -  History of an autoimmune disorder, or an immunosuppressive disorder\n\n          -  Stool sample with occult blood at baseline\n\n          -  Any other medical, psychiatric, social condition, or occupation, in the judgement of\n             the investigator, is a contraindication to the compliance of the protocol or informed\n             consent"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01698060", 
            "org_study_id": "VXA01-001subA"
        }, 
        "intervention": {
            "arm_group_label": "Intestinal Delivery", 
            "intervention_name": "ND1.1", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Prevention of Avian Influenza", 
        "lastchanged_date": "October 1, 2012", 
        "location": {
            "contact": {
                "email": "esandefer@scintipharma.com", 
                "last_name": "Erik Sandefer"
            }, 
            "facility": {
                "address": {
                    "city": "Lexington", 
                    "country": "United States", 
                    "state": "Kentucky"
                }, 
                "name": "Scintipharma"
            }, 
            "investigator": {
                "last_name": "Walter Doll, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of ND1.1 by Delivery Directly to the Ileum Using the InteliSite\u00ae Companion Capsule in Healthy Adult Males", 
        "overall_official": {
            "affiliation": "Vaxart, Inc.", 
            "last_name": "David Liebowitz, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Frequency and magnitude of adverse events", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01698060"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Antibody and T cell responses to HA", 
            "measure": "Immunogenicity", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "Vaxart", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vaxart", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}